Our Science

We are leveraging our library of small molecule inhibitors of the novel target, VCP/p97, to tackle human diseases with severely unmet medical need. Targeting VCP/p9 allows us to exploit cellular dependencies on stress response pathways in cancer as VCP/p97 is a key component of multiple stress pathways that cancer cells rely on to support their abnormal growth and proliferation, disrupting these pathways has been shown to be effective in targeting cancer cells.